Dr. Goldberg has more than 20 years
of experience in the pharmaceutical and
biotechnology industries, ranging from drug
discovery at a Fortune 25 company to chief executive
officer of “virtual” biotechnology companies. Dr. Goldberg
has served as President, CEO and Founder of Transport
Pharmaceuticals, Inc., and President, CEO and co-Founder of Talaria
Therapeutics, which developed the Large Unilamellar Vesicle (LUV) technology.
Talaria Therapeutics was acquired by Esperion Therapeutics (NASDAQ:ESPR)
less than two years after its formation.
Dr. Goldberg was also Vice President of Product development and Regulatory Affairs at GelTex Pharmaceuticals (NASDAQ:GELX), where he was responsible for all biological and clinical development activities at the company, leading to the approval of RenaGel® and WelChol®. He was also Science Coordinator for the Atherosclerosis Research Program at Pfizer Central Research. Dr. Goldberg holds a Ph.D. in Physiology and Biochemistry from Temple University and received post doctoral training at the University of Pennsylvania and at the Specialized Center of Research on Atherosclerosis, University of California, San Diego. He has published extensively in basic and clinical sciences and is the inventor on twelve U.S. patents.
Reconstituting the Reverse
Cholesterol Transport Pathway
LipimetiX Development, LLC.
Dennis I. Goldberg, Ph.D.